Sorafenib for treating head and neck adenocarcinoma of unknown primary site: a case report

The aim of the present study was to report a rare case of head and neck adenocarcinoma with an unknown primary site in a 59-year-old man. After disease progression followed by multiple cycles of chemotherapy and radiotherapy, genetic screening using next-generation sequencing identified vascular end...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Jingxian, Cheng, Chien-shan, Chen, Jie, Lv, Lingling, Shen, Xiaoheng, Zheng, Lan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7683926/
https://www.ncbi.nlm.nih.gov/pubmed/33203264
http://dx.doi.org/10.1177/0300060520964355
Descripción
Sumario:The aim of the present study was to report a rare case of head and neck adenocarcinoma with an unknown primary site in a 59-year-old man. After disease progression followed by multiple cycles of chemotherapy and radiotherapy, genetic screening using next-generation sequencing identified vascular endothelial growth factor A amplification and the TP53 R209Kfs mutation. Treatment with the multi-targeted protein kinase inhibitor sorafenib controlled the patient’s symptoms and improved his quality of life.

Ejemplares similares